Q-Med Breaks Into U.S. Urology Market With Deflux Pediatric VUR Indication
This article was originally published in The Gray Sheet
Executive Summary
Q-Med plans to begin a U.S. pilot study of its Deflux injectable hyaluronic gel product for treatment of stress urinary incontinence early in 2002. The product has been available in Europe for the indication since 1999.